Autoimmune Diseases Treatment
Autoimmune Diseases Treatment
Treatment of autoimmune disease is aimed at one thing: holding inflammation below the level at which it damages tissue, and keeping it there. Everything else on this page follows from that sentence — why the antibody level is not the measurement, why the medicines take months to be judged, why the dose comes down slowly, and why infection screening and vaccination are arranged before immunosuppression begins rather than after. The most common misunderstanding, in both directions, is the belief that the aim is a negative blood test.
The goal is a line, not a negative test
Ask most people what successful treatment of an autoimmune disease looks like and the answer is a negative antibody test. It usually is not, and taking the test as the target produces two errors that go in opposite directions. One person sees a titre fall, concludes the disease has gone, stops the medicine, and the inflammation returns — often in the organ that was being protected. Another sees a titre that has not moved, concludes the treatment is failing, and abandons a regimen that is doing exactly what it was prescribed to do.
What the target actually is, is a line: the level of inflammation below which tissue is not being damaged. In practice it is described as remission, or as low disease activity where remission is not reachable, and it is defined before treatment starts so that both sides know what is being aimed at.
| Measurement | What it contributes |
|---|---|
| Symptoms and examination | Is there inflammation now? The swollen joint count, the rash, the mouth ulcers — measured the same way each time |
| Organ function | Is the organ at risk still doing its job? Kidney function and urine, blood counts, liver tests, thyroid function, lung function as relevant |
| Acute-phase markers | Is inflammation active, and has it settled? Sedimentation rate and C-reactive protein |
| Imaging | Has the structural picture changed, and is what remains active inflammation or damage already done? |
| The person's own function | Can they work, dress, walk and sleep as they need to? The measure that matters most and is recorded least often |
The antibody titre is generally a documented baseline rather than a target, and it is worth stating without qualification: a titre that does not fall is not evidence that treatment has failed. A joint still swollen at six months is. Underneath the target sits the distinction that gives treatment its urgency — activity is the inflammation happening now and is what treatment can change; damage is what has already been laid down, and it is cumulative and largely permanent.
The classes of medicine, and what each one is for
Treatment is built from a small number of classes, and they are combined rather than chosen between. What follows describes what each class is for — not which medicine, and not which dose. Those are decisions for the specialist managing the condition, on the full picture, including what is available locally and what can be monitored.
| Class | What it does | The role it plays |
|---|---|---|
| Glucocorticoids | Dampen inflammation quickly, within days | Bringing a flare under control, and covering the weeks before a slower medicine takes effect. Dose and duration are set by the situation; long-term use carries its own monitoring requirements, which is why the aim is the lowest dose for the shortest time that holds the target |
| Conventional synthetic disease-modifying agents | Modify the underlying process rather than the symptoms, over weeks to months | The backbone of long-term treatment in most of these conditions. They are what allows the steroid dose to come down and stay down |
| Biologic agents | Target a specific step in the immune response, given by injection or infusion | Used where conventional agents have not reached the target, chosen according to the condition and its pattern rather than by how severe the symptoms feel |
| Other immunosuppressive agents | Suppress the immune response more broadly | Used where the condition or the organ at risk calls for it, including in kidney and blood vessel involvement |
| Treatment aimed at the organ rather than the mechanism | Blood pressure control, hormone replacement, bone protection, stomach protection | Not decorative adjuncts: in several conditions these are what actually protects function, and they are part of the plan rather than after it |
| Vaccination and infection prevention | Reduce the risk that treatment creates | Part of the treatment plan, timed around the start of immunosuppression — the detail is in the section below |
Two principles govern how these are combined. The steroid is a bridge rather than a destination: it works fast, and the aim is for the slower medicine to take over so the steroid can be reduced. And the organ-directed treatment runs in parallel rather than afterwards — protecting the kidney, the bone or the gland is not something to add once the immune side is settled.
What nobody should expect from this page is a named medicine or a dose. Which agent is appropriate, whether it is available where you are, and what monitoring it requires are decisions made by the specialist with the full picture in front of them.
Treat to target: set it, measure it, adjust, re-measure
Treat to target is the ordinary name for a simple loop, and it is the thing that separates a plan from a prescription. A target is agreed. Treatment is given. The target is measured at a stated interval. If it has not been reached, treatment is adjusted; if it has been held for a sustained period, reduction is considered. Then it is measured again.
The interval is the part most often got wrong, and it is wrong in both directions. Measuring too soon — a fortnight after a change — reads the change itself rather than its result, and acting on that number is how people end up on more treatment than they need. Measuring too rarely means a loss of control is discovered by the damage it has caused rather than by the markers that precede it. Most of the medicines involved take weeks to months to reach their full effect, and the interval in the plan follows from that rather than from a calendar.
What goes into each measurement is the same short set: symptoms and examination, the organ function tests, the acute-phase markers, and imaging where it is relevant. Recording them the same way each time is what makes the series readable — a joint count done differently at every visit produces a series that means nothing.
Two questions are worth asking at the start: what exactly is the target, and at what interval will it be measured? A plan with answers to both can be followed anywhere the tests can be drawn. Where the condition has been named, the target and interval are set out in its own guide: lupus nephritis at the kidney, and thyroid disorders at the gland, where the measure is a hormone level rather than an inflammation marker.
Flares, and why the dose comes down slowly
A flare is treated along the lines the plan states, and the plan exists so that the decision does not have to be made from scratch while it is happening. What it usually involves is treating any trigger that can be found — an infection, a new medicine, a lapse in adherence — and adjusting the anti-inflammatory treatment for a defined period rather than indefinitely.
The reason a steroid course is tapered rather than stopped is not caution for its own sake. A course suppresses the body's own production of the hormone while it is being taken, and coming off it abruptly leaves the body without enough of it for a period. That is a separate risk from the disease flaring back, and it is why the reduction is scheduled. Stopping a disease-modifying agent abruptly is a different matter again: it removes the thing holding the line, usually without an immediate effect, so the loss of control arrives weeks later and seems unconnected to the decision that caused it.
Three rules follow. Reduction happens after a sustained period of control, not after a good fortnight. It happens one change at a time, so that a later loss of control can be attributed to something rather than to everything. And it happens with a review date attached, because the effect of a reduction is not visible at the moment it is made.
The review after a flare is where the next one is prevented, and it asks four questions in order: was there a trigger, was the treatment actually being taken, was the dose already too low for the target, and has anything else changed.
Infection risk and vaccination, timed before treatment starts
Reducing the immune response reduces the body's ability to deal with infection, and that is the main risk the treatment carries. It is managed rather than accepted, and most of the management happens before the first dose rather than after it.
Three things belong to that window. An infection screen, looking for infections that are latent rather than active and that treatment could reactivate — tuberculosis and hepatitis B among them — because finding them after immunosuppression has begun is a much harder situation than finding them before. A vaccination review, establishing what is current and what is due, because vaccines that need to be given before immunosuppression should be given while the immune system can still respond to them. And a conversation about live vaccines, which are generally avoided once treatment has started and therefore have to be planned around.
Once on treatment the rules are short. Fever is taken seriously rather than watched, and fever with a low white cell count is treated as an emergency until shown not to be. Dental and skin infections are dealt with rather than left. Household members being vaccinated reduces what reaches the person. Which vaccines are appropriate, and when, depends on the treatment, the timing of doses and your own history, and is confirmed by the clinicians managing the condition rather than assumed.
Pregnancy, and why it is planned rather than discovered
Pregnancy and autoimmune disease need to be arranged together, and the reason is that two separate things have to be true at once. The disease needs to be quiescent, because active inflammation during pregnancy is the risk to both the pregnancy and the mother. And the medicines need to be compatible, because several of those used in these conditions are not, and changing them takes months to take effect.
Planning therefore happens before conception rather than after it. Medicines are reviewed, and anything unsuitable is changed in advance with enough time for the change to be judged. The disease is measured, so that whatever happens later can be compared against a baseline. And a monitoring plan is agreed that involves the clinicians managing the condition and the obstetric team working together rather than separately.
Three points are worth stating plainly, because the instincts about them are often wrong. Stopping treatment on discovering a pregnancy is usually the wrong move — it is active disease that threatens the pregnancy, and decisions about medicines are made with the clinical team rather than unilaterally in either direction. Breastfeeding is compatible with some of these medicines and not with others, and that is a specific question rather than a general one. And the period after delivery is a time when several of these conditions become more active, so monitoring continues rather than stopping at birth.
Contraception belongs in the same conversation, for the same reason: several of the medicines used should not be taken during a pregnancy, which makes reliable contraception part of the treatment plan for anyone who could become pregnant.
Living on long-term treatment
Most of what determines the outcome happens between appointments, and the habits that matter are unglamorous. Taking the medicine on the days when nothing hurts, which is the hardest one, because the medicine is working precisely when there is nothing to feel. Keeping a written list of every medicine with its purpose, so that any new prescriber — a dentist, an emergency doctor, a pharmacist abroad — knows what they are looking at. And knowing the two rules that override everything else: what to do in a flare, and what counts as an emergency.
A short list of things that genuinely change the picture. Stop smoking, which is associated with worse outcomes in several of these conditions and reduces the effectiveness of some treatments. Keep vaccinations current, on the timing your team advises. Treat infections rather than waiting for them to settle. Protect the bone — because steroids and reduced mobility both cost bone, and this is one of the things that is measured rather than assumed. And keep moving: preserving function and staying at work are part of the plan rather than rewards for completing it.
The part people find hardest is the length: treatments measured in years, taken while feeling well, monitored by numbers that matter more than symptoms. The reason to hold to it is not abstract — the damage treatment prevents is the damage that does not show up. Where a patient wants a combined approach with traditional Chinese medicine, our traditional Chinese medicine department has been in place since the hospital was founded and our Guoyi Hall is where senior physicians recognised at national and Guangdong provincial level see patients; it is an addition to the prescribed treatment, never a substitute. What to monitor and how often is set out on the living-with-it page.